These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
831 related articles for article (PubMed ID: 17697278)
1. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M; Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278 [TBL] [Abstract][Full Text] [Related]
2. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. van den Berg CH; Smit C; Bakker M; Geskus RB; Berkhout B; Jurriaans S; Coutinho RA; Wolthers KC; Prins M Eur J Epidemiol; 2007; 22(3):183-93. PubMed ID: 17334821 [TBL] [Abstract][Full Text] [Related]
3. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390 [TBL] [Abstract][Full Text] [Related]
4. Methadone maintenance and hepatitis C virus infection among injecting drug users. Crofts N; Nigro L; Oman K; Stevenson E; Sherman J Addiction; 1997 Aug; 92(8):999-1005. PubMed ID: 9376782 [TBL] [Abstract][Full Text] [Related]
5. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Holtzman D; Barry V; Ouellet LJ; Des Jarlais DC; Vlahov D; Golub ET; Hudson SM; Garfein RS Prev Med; 2009 Aug; 49(1):68-73. PubMed ID: 19410600 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. Chetwynd J; Brunton C; Blank M; Plumridge E; Baldwin D N Z Med J; 1995 Sep; 108(1007):364-6. PubMed ID: 7566775 [TBL] [Abstract][Full Text] [Related]
7. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Palmateer N; Kimber J; Hickman M; Hutchinson S; Rhodes T; Goldberg D Addiction; 2010 May; 105(5):844-59. PubMed ID: 20219055 [TBL] [Abstract][Full Text] [Related]
8. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. Lindenburg CE; Krol A; Smit C; Buster MC; Coutinho RA; Prins M AIDS; 2006 Aug; 20(13):1771-5. PubMed ID: 16931942 [TBL] [Abstract][Full Text] [Related]
9. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention. Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367 [TBL] [Abstract][Full Text] [Related]
10. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Emmanuelli J; Desenclos JC Addiction; 2005 Nov; 100(11):1690-700. PubMed ID: 16277629 [TBL] [Abstract][Full Text] [Related]
11. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? de Vos AS; van der Helm JJ; Matser A; Prins M; Kretzschmar ME Addiction; 2013 Jun; 108(6):1070-81. PubMed ID: 23347124 [TBL] [Abstract][Full Text] [Related]
12. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction. Hallinan R; Byrne A; Dore GJ Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors. Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285 [TBL] [Abstract][Full Text] [Related]
14. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning. Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463 [TBL] [Abstract][Full Text] [Related]
15. The role of needle exchange programs in HIV prevention. Vlahov D; Junge B Public Health Rep; 1998 Jun; 113 Suppl 1(Suppl 1):75-80. PubMed ID: 9722812 [TBL] [Abstract][Full Text] [Related]
16. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Matser A; Urbanus A; Geskus R; Kretzschmar M; Xiridou M; Buster M; Coutinho R; Prins M Addiction; 2012 Mar; 107(3):614-23. PubMed ID: 21919987 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Zamani S; Ichikawa S; Nassirimanesh B; Vazirian M; Ichikawa K; Gouya MM; Afshar P; Ono-Kihara M; Ravari SM; Kihara M Int J Drug Policy; 2007 Oct; 18(5):359-63. PubMed ID: 17854723 [TBL] [Abstract][Full Text] [Related]
18. "I inject less as I have easier access to pipes": injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. Leonard L; DeRubeis E; Pelude L; Medd E; Birkett N; Seto J Int J Drug Policy; 2008 Jun; 19(3):255-64. PubMed ID: 18502378 [TBL] [Abstract][Full Text] [Related]
19. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555 [TBL] [Abstract][Full Text] [Related]
20. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. van de Laar TJ; Langendam MW; Bruisten SM; Welp EA; Verhaest I; van Ameijden EJ; Coutinho RA; Prins M J Med Virol; 2005 Dec; 77(4):509-18. PubMed ID: 16254983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]